BioSpace News Archive

GE HealthCare Technologies Inc. announced the pricing of the previously announced secondary underwritten public offering of 13,000,000 shares of its common stock at a public offering price of $82.25 per share.

This announcement is a summary of Bioretec Ltd’s financial statements bulletin for January-December 2023.

Pharvaris, a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema attacks, announced the extraordinary general meeting of shareholders will take place on Wednesday, March 6, 2024, at 12:00 CST.

Y-mAbs Therapeutics, Inc. announced that it will report its financial results for the quarter and full year ended December 31, 2023, on Thursday, February 29, 2024, after the close of the U.S. financial markets.

Chromocell Therapeutics Corporation announced the pricing of its initial public offering of 1,100,000 shares of common stock at a public offering price of $6.00 per share.

Arcutis Biotherapeutics, Inc. announced that it will report its fourth quarter and full year financial results and provide a business update on Tuesday, February 27, 2024.

Hepion Pharmaceuticals, Inc. announced that it has entered into a definitive agreement for the immediate exercise of an outstanding Series B common stock purchase warrant held by an institutional investor to purchase an aggregate of 980,393 shares of Hepion common stock for gross proceeds to the Company of approximately $2.0 million.

XOMA Corporation announced it has entered an agreement to acquire Kinnate Biopharma Inc. for a base cash price of $2.3352 per share and an additional cash amount of not more than $0.2527 per share at the closing of the merger plus a non-transferable contingent value right.

For the 11th consecutive year, Thermo Fisher Scientific’s pharma and biopharma customers recognized its contract manufacturing excellence through the annual CDMO Leadership awards sponsored by Outsourced Pharma and Life Science Connect.

MDxHealth SA, a commercial-stage precision diagnostics company, announced that Jan Pensaert has stepped down from the Board of Directors of mdxhealth.